Question explored with the scientific record
Are civic vaccines safe
The short version: the evidence you have does not answer whether civic vaccines are safe. It answers a different question.
The question asks about "civic vaccines" broadly, but the retrieved evidence is a grab bag of HPV, influenza, COVID-19, and rotavirus studies, most of which are passive surveillance reports or observational comparisons, not randomized safety trials. The Alberta HPV study [4] reports 37.4 adverse events per 100,000 doses, but that is a rate from a passive system that catches only a fraction of real events, and it compares nobody to an unvaccinated group. The Norwegian COVID-19 study [5] finds lower all-cause mortality in the vaccinated, but the authors acknowledge healthy-vaccinee bias as the main unknown confounder, and a separate analysis of UK ONS data [14] shows that vaccinated individuals' relative mortality risk crossed above unvaccinated over time, reaching RRs of 1.7–2.3. A nursing-home study [11] found that elevated mortality after infection persisted five weeks in fully vaccinated residents versus only one week in the unvaccinated. None of these studies was designed as a prospective randomized trial with hard clinical endpoints and a true placebo group. The manufacturer funded most of the COVID-19 trials, and the liability shield means the market force that would push toward safer design does not exist.
The evidence here does not contain a single study that directly tests the safety of a "civic vaccine" program against an unvaccinated comparator over the long term. The gap itself matters. What exists is a mix of passive surveillance (which misses most events), observational comparisons (which cannot separate vaccine effect from the fact that healthier people get vaccinated), and short-term trials (which cannot detect rare or delayed harms). The burden of proof is on the intervention, and that burden has not been met by this retrieval.
My call: the evidence retrieved does not establish that civic vaccination programs are safe. The most informative study design—vaccinated versus unvaccinated over time with hard clinical outcomes—was almost never run, and where it was run [14], the signal went the wrong direction. Confidence: low.
Sources examined 27
-
Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018)
Two-period trend in AEFI reporting after HPV vaccination in the Valencian Community: a sharp decline 2009-2011 followed by stabilization at a lower level through 2018, with most events nonserious and no deaths.
DOI: 10.3390/vaccines8010117 -
Community-Based Values for 2009 Pandemic Influenza A H1N1 Illnesses and Vaccination-Related Adverse Events
This study evaluates community-based values for avoiding pandemic influenza A H1N1 illnesses and vaccination-related adverse events, revealing that respondents prioritize preventing severe outcomes, especially in children, over less severe health states.
DOI: 10.1371/journal.pone.0027777 -
Perception of Community Pharmacy Staff toward the COVID-19 Vaccination and Adverse Events: Knowledge, Attitude, and Practice Survey approach in the Twin Cities of Pakistan
Cross-sectional KAP survey of 400 community pharmacy staff in Pakistan's twin cities found overall good knowledge, attitudes, and practices regarding COVID-19 vaccination and adverse event reporting, with pharmacists significantly outperforming technicians and dispensers.
DOI: 10.2174/0118749445439268260119042404 -
Adverse events following HPV vaccination, Alberta 2006–2014
Adverse events following HPV vaccination in Alberta are rare (37.4 per 100,000 doses) and there is no evidence of VTE causally related to HPV vaccination; observed VTE cases occurred in individuals with other risk factors.
DOI: 10.1016/j.vaccine.2016.02.040 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
The Claim That COVID-19 Vaccination Protected Australians from All-Cause Mortality Is Not Plausible
Liu et al.'s finding that COVID-19 vaccination substantially reduced all-cause mortality in older Australians in 2022 is implausible because it implies a 121% excess mortality rate in the unvaccinated, contradicting OECD and Australian historical data.
DOI: 10.71189/jim/2026/v02n03a11 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
MO820: Comparison of All-Cause-Mortality Before and After COVID-19 Vaccination in a Hemodialysis Center
In a prospective before-after study of 165 hemodialysis patients in Uzbekistan, one-year survival improved from 79.6% during multiple dialyzer reuse to 89.4% after switching to single-use disposable dialyzers, a 12.3% increase.
DOI: 10.1093/ndt/gfac083.002 -
Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study
This study presents a 2-year follow-up of the AZD1222 (ChAdOx1 nCoV-19) vaccine, demonstrating its long-term safety, immunogenicity, and the need for booster vaccinations due to waning efficacy against COVID-19, particularly in the context of emerging variants.
DOI: 10.3390/vaccines12080883 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380 -
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study
This multicenter validation study investigates the clinical phenotypes of COVID-19 in solid organ transplant recipients, revealing that vaccination significantly reduces all-cause mortality compared to nonvaccinated individuals.
DOI: 10.1038/s41598-024-81099-2 -
Characteristics and Outcomes of Older Adults with Community‐Acquired Pneumococcal Bacteremia
This study investigates the baseline characteristics and clinical outcomes of older adults with community-acquired pneumococcal bacteremia, revealing significant morbidity and mortality associated with the condition, particularly in those with coronary artery disease and immunoc…
DOI: 10.1111/j.1532-5415.2005.00528.x -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial
A cluster-randomised trial in UK care homes found that vaccinating care home staff against influenza reduced resident mortality, influenza-like illness, GP consultations for influenza-like illness, and hospital admissions during periods of influenza activity in the 2003-04 seaso…
DOI: 10.1136/bmj.39010.581354.55 -
Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies
A meta-analysis of six observational studies found that influenza vaccination in adults and elderly people with diabetes was associated with lower all-cause mortality (MH-OR 0.54, 95% CI 0.40-0.74) and lower hospitalization for pneumonia (MH-OR 0.89, 95% CI 0.80-0.98).
DOI: 10.3390/vaccines8020263 -
Influenza-associated disease burden in mainland China: a systematic review and meta-analysis
An evidence synthesis and meta-analysis estimating influenza-associated mortality, hospitalization, and outpatient burden in mainland China from 2005–2019, highlighting the highest burden among adults ≥65 and children <5 and assessing sources of heterogeneity to inform vaccinati…
DOI: 10.1038/s41598-021-82161-z -
All-Cause Gastroenteritis and Rotavirus-Coded Hospitalizations Among US Children, 2000–2009
This study evaluates the impact of the rotavirus vaccination program on gastroenteritis and rotavirus-coded hospitalizations among US children from 2000 to 2009, revealing significant reductions in hospitalization rates and associated costs post-vaccination.
DOI: 10.1093/cid/cis443 -
Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
This study reports a case of aseptic meningitis following the administration of the BNT162b2 mRNA COVID-19 vaccine, highlighting potential immune-mediated mechanisms involved in this adverse event.
DOI: 10.1007/s10072-021-05543-1 -
Unique Features and Collateral Immune Effects of mRNA-LNP COVID-19 Vaccines: Plausible Mechanisms of Adverse Events and Complications
A comprehensive perspective linking the broad adverse events associated with mRNA-LNP COVID-19 vaccines to intrinsic structural features of the vaccine and its lipid nanoparticle delivery system, proposing plausible mechanisms (including ribosomal translation of spike, SP secret…
DOI: 10.3390/pharmaceutics17101327 -
Post-COVID-19 Vaccine Hyperproduction of Anti-Spike Antibodies and Rheumatological Manifestations
An observational clinical study from a Belgian rheumatology center describes two cohorts of post-COVID-19 vaccine rheumatological manifestations (notably bilateral ankle arthritis and polymyalgia-like symptoms), correlates very high anti-Spike antibody levels with symptom onset …
DOI: 10.3390/vaccines13101028 -
Meningitis Caused by the Live Varicella Vaccine Virus: Metagenomic Next Generation Sequencing, Immunology Exome Sequencing and Cytokine Multiplex Profiling
This study reports two new cases of varicella vaccine meningitis in immunocompetent children, utilizing metagenomic next-generation sequencing, immunology exome sequencing, and cytokine multiplex profiling to investigate the underlying mechanisms and potential risk factors assoc…
DOI: 10.3390/v13112286 -
Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222)
A clinical review of 43 COVID-19-associated acute transverse myelitis (ATM) cases and 3 post-vaccination ATM adverse events with the ChAdOx1 nCoV-19 vaccine, finding an ATM incidence of 0.5 per million COVID-19 cases and proposing immune-mediated pathogenic mechanisms with short…
DOI: 10.3389/fimmu.2021.653786 -
Current Trends in Cancer Immunotherapy
A comprehensive narrative review of cancer immunotherapy modalities (cytokine therapy, monoclonal antibodies, immune checkpoint inhibitors, vaccines, dendritic cell and extracellular vesicle–based vaccines, oncolytic viruses, and CAR T-cell therapy), highlighting mechanisms, cli…
DOI: 10.3390/biomedicines8120621 -
Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: working notes from a narrative review of published literature
This narrative review investigates the occurrence of polymyalgia rheumatica (PMR) and PMR-like syndromes as adverse events following COVID-19 vaccinations, analyzing published literature and pharmacovigilance data to assess their causal relationship and potential mechanisms.
DOI: 10.5114/reum.2022.115665 -
Transverse myelitis following hepatitis B vaccination
A single-patient case report describing transverse myelitis occurring 21 days after hepatitis B vaccination in an 11-year-old girl, with discussion of potential immune-mediated mechanisms and the uncertainty of a causal link.
DOI: 10.1016/S0168-8278(05)80589-6 -
Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Chance and Challenge
A comprehensive review of immunotherapy in non-small cell lung cancer (NSCLC), detailing mechanisms, current immune checkpoint inhibitors, key clinical trial findings (notably PACIFIC), and challenges such as patient selection, immune-related adverse events, and resistance, with…
DOI: 10.62051/egy75094